Oculis Holding AG
OCS17.610USD
-0.030-0.17%
시장 운영 시간 （ET）시세는 15분 지연됩니다
978.42M시가총액
손실P/E TTM
자세한 내용은 Oculis Holding AG 회사
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
회사 정보
종목 코드 OCS
회사 이름Oculis Holding AG
상장일Mar 03, 2023
CEODr. Riad Sherif, M.D.
직원 수49
유형Ordinary Share
회계 연도 종료Mar 03
주소Bahnhofstrasse 20
도시ZUG
증권 거래소NASDAQ Global Market Consolidated
국가Switzerland
우편 번호6300
전화41417113960
웹사이트https://oculis.com/
종목 코드 OCS
상장일Mar 03, 2023
CEODr. Riad Sherif, M.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dhr. Martijn Kleijwegt ,
Dhr. Martijn Kleijwegt ,
Independent Director
Independent Director
470.97K
--
Mr. Pall Ragnar Johannesson
Mr. Pall Ragnar Johannesson
Chief Strategy Officer
Chief Strategy Officer
268.83K
+7.87%
Ms. Sylvia Cheung, CPA
Ms. Sylvia Cheung, CPA
Chief Financial Officer
Chief Financial Officer
72.06K
+7.86%
Ms. Geraldine O'Keeffe
Ms. Geraldine O'Keeffe
Independent Director
Independent Director
20.59K
--
Dr. Bastian Dehmel, M.D.
Dr. Bastian Dehmel, M.D.
Head - Development
Head - Development
--
--
Mr. Anthony A. (Tony) Rosenberg
Mr. Anthony A. (Tony) Rosenberg
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Riad Sherif, M.D.
Dr. Riad Sherif, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Christina M. Ackermann
Ms. Christina M. Ackermann
Independent Director
Independent Director
--
-100.00%
Mr. Lionel Carnot
Mr. Lionel Carnot
Independent Director
Independent Director
--
--
Dr. Pravin U. Dugel, M.D.
Dr. Pravin U. Dugel, M.D.
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dhr. Martijn Kleijwegt ,
Dhr. Martijn Kleijwegt ,
Independent Director
Independent Director
470.97K
--
Mr. Pall Ragnar Johannesson
Mr. Pall Ragnar Johannesson
Chief Strategy Officer
Chief Strategy Officer
268.83K
+7.87%
Ms. Sylvia Cheung, CPA
Ms. Sylvia Cheung, CPA
Chief Financial Officer
Chief Financial Officer
72.06K
+7.86%
Ms. Geraldine O'Keeffe
Ms. Geraldine O'Keeffe
Independent Director
Independent Director
20.59K
--
Dr. Bastian Dehmel, M.D.
Dr. Bastian Dehmel, M.D.
Head - Development
Head - Development
--
--
Mr. Anthony A. (Tony) Rosenberg
Mr. Anthony A. (Tony) Rosenberg
Independent Chairman of the Board
Independent Chairman of the Board
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Tue, Jun 3
마지막 업데이트: Tue, Jun 3
주주
주주 유형
주주
주주
비율
EQT Life Sciences
11.05%
Earlybird Venture Capital
4.89%
Pivotal Bioventure Partners Investment Advisor LLC
4.42%
BVCF Management, Ltd.
4.21%
Novartis AG
3.29%
Other
72.14%
주주
주주
비율
EQT Life Sciences
11.05%
Earlybird Venture Capital
4.89%
Pivotal Bioventure Partners Investment Advisor LLC
4.42%
BVCF Management, Ltd.
4.21%
Novartis AG
3.29%
Other
72.14%
주주 유형
주주
비율
Venture Capital
26.17%
Corporation
3.29%
Individual Investor
3.06%
Investment Advisor/Hedge Fund
2.52%
Investment Advisor
1.67%
Hedge Fund
0.49%
Research Firm
0.09%
Bank and Trust
0.03%
Pension Fund
0.01%
Other
62.66%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
51
19.47M
37.40%
+1.77M
2025Q1
51
19.44M
37.35%
+1.93M
2024Q4
86
15.00M
31.97%
-10.87M
2024Q3
87
16.29M
41.43%
-9.17M
2024Q2
88
16.63M
42.28%
-9.14M
2024Q1
91
16.14M
42.22%
-11.25M
2023Q4
93
17.20M
46.87%
-6.97M
2023Q3
92
16.51M
48.34%
-4.37M
2023Q2
91
16.72M
48.91%
-4.14M
2023Q1
88
16.73M
51.20%
+4.73M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
EQT Life Sciences
5.75M
11.05%
+425.53K
+7.99%
Dec 31, 2024
Earlybird Venture Capital
2.54M
4.89%
+2.54M
--
Dec 31, 2024
Pivotal Bioventure Partners Investment Advisor LLC
2.30M
4.42%
+563.08K
+32.40%
Mar 31, 2025
BVCF Management, Ltd.
2.19M
4.21%
+121.79K
+5.88%
Nov 27, 2024
Novartis AG
1.71M
3.29%
-464.38K
-21.32%
Feb 13, 2024
abrdn Inc.
1.25M
2.41%
+243.69K
+24.14%
Mar 31, 2025
Sherif (Riad M.D.)
644.75K
1.24%
-233.73K
-26.61%
Dec 31, 2024
Nan Fung Life Sciences
514.70K
0.99%
+78.32K
+17.95%
Mar 31, 2025
Stefnir hf.
510.50K
0.98%
--
--
May 31, 2025
Kleijwegt (Martijn)
470.97K
0.9%
+470.97K
--
Dec 31, 2024
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
SPDR SSGA US Small Cap Low Volatility Index ETF
0.12%
Even Herd Long Short ETF
0%
SPDR SSGA US Small Cap Low Volatility Index ETF
비율0.12%
Even Herd Long Short ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
